Gilead Sciences, Inc. (GILD) on Friday reported that the Phase 3 ASCENT-07 study, evaluating Trodelvy versus chemotherapy as a first-line treatment after endocrine therapy in HR+/HER2-negative metastatic breast cancer, did not meet its primary endpoint of progression-free survival (PFS).
Trodelvy is currently being studied in multiple Phase 3 trials across various tumor types.
The drug is approved in more than 50 countries for second-line or later treatment of metastatic triple-negative breast cancer (TNBC) and in over 40 countries for certain patients with pre-treated HR+/HER2-negative metastatic breast cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.